Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Retained Earnings (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Retained Earnings for 10 consecutive years, with -$1.7 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings changed 0.32% to -$1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.7 billion through Dec 2025, changed 0.32% year-over-year, with the annual reading at -$1.7 billion for FY2025, 0.32% changed from the prior year.
  • Retained Earnings for Q4 2025 was -$1.7 billion at Akebia Therapeutics, down from -$1.7 billion in the prior quarter.
  • The five-year high for Retained Earnings was $9000.0 in Q1 2021, with the low at -$1.7 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$965.6 million, with a median of -$1.5 billion recorded in 2022.
  • The sharpest move saw Retained Earnings surged 166.67% in 2021, then plummeted 27857783.33% in 2025.
  • Over 5 years, Retained Earnings stood at $6000.0 in 2021, then changed by 0.0% to $6000.0 in 2022, then plummeted by 26815933.33% to -$1.6 billion in 2023, then dropped by 4.31% to -$1.7 billion in 2024, then decreased by 0.32% to -$1.7 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.7 billion, -$1.7 billion, and -$1.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.